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Abstract
Background: Inhibitors of tumor necrosis factor alpha (TNF-α) are current mainstay of therapies for rheumatoid
arthritis (RA). The decision when to withdraw TNF-α inhibitors after achieving remission and the incidence of
relapse rates with elective discontinuation are both important questions that demand intense survey in these
patients. In this meta-analysis we aimed to estimate the magnitude of relapse rate after elective TNF-α inhibitor
discontinuation in RA patients with remission.
Methods: Systematic searches of PubMed/MEDLINE, Cochrane Library databases, grey literature (unpublished and
ongoing trials) from the WHO International Clinical Trials Registry Platform and the US National Institutes of Health
were performed for studies reporting the outcomes of elective discontinuation of TNF-α inhibitor in RA patients
after remission. Random-effects models for meta-analyses were conducted on extracted data.
Results: Out of 390 references screened, 16 RCTs were included. Meta-analysis of 1264 patient data revealed a
relapse rate of 0.47 (95% CI 0.41–0.54). Sensitivity analysis showed that none of the studies had higher influence on
the results.
Conclusions: Almost half of all the RA patients in remission relapse after elective TNF-α inhibitor discontinuation.
This information might be useful when considering this management option with individual patients.
Keywords: DMARDs (synthetic), TNF-α inhibitors, Rheumatoid arthritis, Treatment discontinuation, Relapse
Background
Rheumatoid arthritis (RA) is a chronic multisystem
autoimmune inflammatory disease that leads to signifi-
cant joint inflammation with damage and deformity. The
disease has an annual incidence of three cases per
10,000, and a prevalence of 1%, increasing with age and
peaking between the ages of 35 and 50 years [1]. RA af-
fects all populations, with few ethnic variations (e.g., 5–
6% in some Native American groups vs. 0.8% in
black-Caribbeans) [1, 2]. Women are affected three
times more often than men however sex differences tend
to diminish in older age groups with a female to male
ratio of 2:1 after the fifth decade of life [1, 3].
The pharmacological therapies for RA comprise
nonsteroidal anti-inflammatory drugs (NSAIDs),
corticosteroids and the disease-modifying antirheu-
matic drugs (DMARDs). The DMARDs include
non-biologic (e.g. methotrexate) and biologic agents
(TNF-α inhibitor drugs and non TNF-α biologics)
that halt the progression of RA by reducing inflam-
mation, preventing joint damage and maintaining the
integrity of joints [1].
The TNF-α inhibitors etanercept, infliximab, certolizu-
mab pegol, adalimumab, and golimumab, are a class of
biologic DMARDs directed towards the TNF-α proin-
flammatory cytokine, and can be administered either
subcutaneously or intravenously. TNF-α inhibitors have
an established role in the induction and maintenance of
remission in patients with RA [4]. However, suppression
of TNF-α also leads to a range of adverse effects
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including the emergence of antinuclear antibodies
(ANAs), generation of antibodies against these com-
pounds, infections (including tuberculosis), increased risk
of cancer, heart failure, demyelinating disorders, and bone
marrow suppression [5]. Immunogenicity has been shown
to occur in patients receiving adalimumab and infliximab,
potentially leading to decreased drug efficacy [6]. The risk
of developing such adverse events, the inconvenience of
parenteral administration, and the high cost of these
agents raised the possibility of elective withdrawal in RA
patients with a considerable disease-free period and in
whom the treatment objectives were achieved. However,
the continuation of TNF-α inhibitor therapy, in RA pa-
tients in remission or low disease activity, increased the
probability of sustained response (whether remission or
low disease activity) and retarded radiographic progression
in a number of published meta-analyses [7, 8]. Further-
more, the incidence of serious adverse events, serious in-
fection, malignancy, and scores of improvement of tender
and swollen joints were not significantly different between
strategies favoring continuation and those with elective
discontinuation after remission with almost half of the pa-
tients withdrawing biologicals maintaining low disease ac-
tivity [6, 7].
Though elective TNF-α inhibitor discontinuation is
justified in several RA patients, there is a lack of suffi-
cient data to guide the decision. Further, the course of
action post-withdrawal also remains to be understood,
although a decision based on sustained remission has
been proposed [9]. Nonetheless, a consensus about pa-
tient selection and the timing of withdrawal remains to
be reached.
As an initial step to address these issues, we investi-
gated whether TNF-α inhibitors can be withdrawn in
general. To this end, we performed a meta-analysis of
studies investigating the relapse rates after elective with-
drawal of TNF-α inhibitor therapy in RA patients.
Methods
Inclusion criteria
1- Studies that included RA patients classified according
to either the American Rheumatism Association 1987
revised criteria for the classification of RA or the 2010
American College of Rheumatology (ACR)/European
League Against Rheumatism (EULAR) RA classification
criteria were used [10, 11].
2- Studies that investigated the relapse rate following
elective withdrawal of TNF-α inhibitors (adalimumab, cer-
tolizumab pegol, etanercept, golimumab, and infliximab)
as a first line or non first line biologic in patients with RA.
Literature search
Literature search from the earliest available date to
March 2016 was performed in PubMed/MEDLINE and
the Cochrane Library databases, and grey literature (un-
published and ongoing trials) was assessed from the
WHO International Clinical Trials Registry Platform
(http://www.who.int/ictrp/en/) and the US National In-
stitutes of Health (https://clinicaltrials.gov/) using the
keywords “adalimumab” or “infliximab” or “golimumab”
or “certolizumab pegol” or “etanercept” or “biological
Products” and “Arthritis, Rheumatoid” and “withdrawal”
or “withdrawn” or “discontinue” or “discontinuation” or
“stop” or “stopped.” The possibilities of finding all rele-
vant publications were increased by not setting the limi-
tations on language, year, or status during the initial
search. The reference lists of included articles were also
screened manually for additional studies. The commen-
taries and conference proceedings, however, were
excluded.
Data extraction and methodological quality assessment
The reviewers (F. Alokaily & S. AlRashidi) independently
screened for potentially relevant article titles and ab-
stracts based on the inclusion criteria. Also, full text arti-
cles were retrieved wherever necessary. Authors were
involved independently in all stages of study selection
and data extraction.
The methodological quality of each selected random-
ized study was assessed by the modified Jadad scale sys-
tem [12]. The criteria for evaluation were:
randomization, blinding, withdrawals, dropouts, inclu-
sion/exclusion criteria, adverse effects, and statistical
analysis. The evaluated scores of studies ranged from 0
to 5 points. A study with a score of ≥3 was considered
as of good quality. The quality of non-randomized trials
was evaluated by CASP (The Critical Appraisal Skills
Programme) checklist for Cohort study [13]. If ≥5 of the
questions in CASP provided positive results about a
non-randomized trial, then the study was considered
high quality.
Statistical analysis
Meta-analysis of the included studies was conducted
using relapse rate with 95% confidence interval (CI).
Pooled relapse rate with 95% confidence interval was es-
timated incorporating fixed-effects model (based on the
Mantel-Haenszel method) or random-effects model
(based on the DerSimonian-Laird method) [14, 15].
Presence of heterogeneity was tested by Q-statistic [16]
and quantified by I2-index [17]. Q-statistic evaluated the
presence of heterogeneity among the selected studies.
Significant heterogeneity was marked by p-value of less
than 0.05. The I2-index quantified the amount of hetero-
geneity among the selected studies. I2values of 25, 50
and 75% suggested low, moderate and high degrees of
heterogeneity, respectively. If there was no significant
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heterogeneity fixed-effects model was used; otherwise,
random-effects model was used.
Sensitivity Analysis: To investigate the validity and ro-
bustness of meta-analysis the leave-one-out sensitivity
method was applied to establish the robustness of the
meta-analysis results.
Cumulative meta-analysis: Studies were included
chronologically to identify the consistency in the result
of selected studies.
Publication Bias: Publication bias was examined visually
by producing a funnel plot where the standard error of
the estimated event rates was plotted against the logit
event rates [18]. If asymmetry in funnel plot was observed
the trim and fill method was adopted to assess the impact
of publication bias [19]. Ideally, approximately similar
number of studies are expected to fall on either side of the
plot. In case of asymmetry in the number of studies plot-
ted, the trim and fill method plots the possibly missing
studies. The number of missing studies plotted correlates
proportionately with the publication bias.
All meta-analyses were executed using the Compre-
hensive Meta-analysis Software, Version 2 (Biostat, En-
glewood, NJ, USA).
Results
A total of 390 citations were identified from all data-
bases. Screening excluded 351 abstracts, reviews and un-
published trials without results. After a further screening
of titles and abstracts, 13 citations were excluded be-
cause of inappropriate protocols or outcomes. Out of 26
studies, 10 appeared to be duplicates. Thus, 16 studies
(n = 13, published and n = 3, unpublished) were finally
eligible (Fig. 1; Tables 1 and 2). Ten studies were con-
ducted in Europe, five were conducted in Japan, and one
was conducted in Europe, Latin America, Asia and
Australia. Seven studies were randomized, seven were
observational/prospective, whereas the remaining two
were retrospective (Table 1). Criteria for TNF-α inhibitor
withdrawal were based on the DAS28/44 scoring system
in 11 studies, clinical parameters in one study, and un-
defined in four studies. Duration of follow-up after with-
drawal was ≥12months in 12 studies, and < 12months
in the remaining four studies (Table 2).
The Jadad score was 3 in four out of the five identified
RCTs, and 2 in the remaining RCT by Moghadam et al.
(Table 3). The different score in the study by Moghadam
et al. was due to its open label randomized study design.
All non-RCTs were of high quality (Table 4).
The meta-analysis, conducted in 1264 RA participants
from 16 studies, showed that the pooled relapse rate
after elective withdrawal of anti-TNF therapy was 0.47;
95% CI 0.41–0.54 (Fig. 2). As significant heterogeneity
was observed (Cochrane’s Q-statistics = 48.27; p-value:
0.00 and I2 = 68.92%), a random-effects-model was used.
Sensitivity analysis, assessing the influence of individual
studies on the pooled relapse rate by omitting individual
studies at each step, suggested that no individual study
significantly affected the pooled relapse rate, thus confirm-
ing the robustness of the meta-analysis results (Fig. 3).
Cumulative meta-analysis of the 16 studies showed
that subsequent studies increased the precision of the
point estimation (Fig. 4). No substantive change oc-
curred in the direction or magnitude of the estimation.
The shape of the funnel plot did not reveal a clear evi-
dence of asymmetry, suggesting no publication bias (Fig. 5).
Furthermore, imputation plotted no missing studies on the
right side. The trim and fill method, adopted to assess the
impact of publication bias, showed that the point estimate
and 95% confidence interval for the combined relapse rates
remained unchanged after trim and fill test (0.45; 95% CI =
0.38–0.51).
Discussion
The current pharmacological treatment of RA is based
on early intensive therapy with synthetic DMARDs in
order to achieve clinical remission. If the latter is not
Fig. 1 Flowchart for identification of studies used
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met, further options include increasing the dose of
DMARD, adding another synthetic DMARD, or combin-
ing the original DMARD with a biologic agent such as
TNF-α inhibitors [1]. However, professional guidelines
do not provide clear recommendations regarding man-
agement strategies once remission, or stable low disease
activity, is achieved [1]. Similarly, there is a limited
amount of evidence regarding whether, when, how and
in whom TNF-α inhibitors can be safely and effectively
withdrawn in this context.
In addition to the achievement of remission or stable
low disease activity, reasons for TNF-α inhibitor treat-
ment discontinuation include patient preference, cost is-
sues, and adverse effects. Patient surveys have reported
that the lack of efficacy and injection reactions, e.g. pain,
burning, discomfort, redness, and swelling, were the
main factors responsible for treatment discontinuation
[20]. However, the uncertainty regarding the magnitude
of the overall risk of relapse is an important issue when
discussing the option of TNF-α inhibitor treatment
withdrawal with RA patients. The availability of robust
data regarding the relapse rate in these patients might
assist with treatment decisions, as well as informing fu-
ture guidelines on RA management. This is particularly
so as TNF-α inhibitor withdrawal is particularly
common in clinical practice. Ramiro et al., investigated
the self-reported discontinuation rates of anti-TNF drugs
in RA patients (n = 2225) in the National Data Bank for
Rheumatic Disease, a longitudinal observational study of
RA outcomes [21]. Discontinuation of the first TNF-α
inhibitor was observed in 1069 (48.0%) of RA patients,
with an annual rate of discontinuation of 0.17 (95% CI
0.16 to 0.18). Out of 988 patients who started a second
TNF-α inhibitor, 481 (48.7%) reported treatment with-
drawal, with an annual discontinuation rate of 0.19 (95%
CI 0.17 to 0.21). Older age, smoking, higher comorbidity
index, and a higher score of the poly-symptomatic dis-
tress scale at baseline independently predicted treatment
discontinuation, whereas the concomitant treatment
with methotrexate reduced the probability of discontinu-
ation [21]. Similar discontinuation rates have been re-
ported in other observational studies [22, 23].
Our meta-analysis of 16 RCTs on RA patients showed
a relatively high (47%) pooled relapse rate after complete
elective withdrawal of TNF-α inhibitors. There was sig-
nificant heterogeneity among studies, however sensitivity
analysis ruled out the influence of individual studies on
the pooled relapse rate. Furthermore, barring one RCT,
all identified studies were considered as having a high
methodological quality, i.e. a clearly defined study aim,
Table 1 Study characteristics
Study characteristics
S.No Study Region Type of study Source of
funding
1 Quinn et al., 2005 Europe (United Kingdom) Randomized controlled trial Not disclosed
2 Nawata et al., 2008 Asia (Japan) Observational/prospective Government
3 Brocq et al., 2009 Europe (France) Observational/prospective Not disclosed
4 Tanaka et al., 2010 Asia (Japan) Observational/prospective Government
5 van den Broek et al.,
2011
Europe (Netherland) Randomized, multicenter, single blind Not disclosed
6 van der Maas et al.,
2012
Europe (Netherland) Observational/prospective Not disclosed
7 Harigai et al., 2012 Asia (Japan) Observational/retrospective Government
8 Hirata et al., 2013 Asia (Japan) Observational/prospective Government
9 Smolen et al., 2013 Europe, Latin America, Asia, Australia Randomized controlled trial Industry
10 Iwamoto et al., 2014 Asia (Japan) Observational/prospective Not disclosed
11 Kádár et al., 2014 Europe (Hungary) Retrospective, multicenter, cohort Government
12 Tanaka et al., 2015 Europe (Hungary) Observational/prospective Government
13 Moghadam et al.,
2016
Europe (Netherland) Randomized controlled trial, multicenter,
open label
Government
14 NCT00808509
(ADMIRE)
Europe (Sweden) Randomized, parallel group, open label Industry
15 NCT00858780
(DOSERA)
Europe (Denmark, Finland, Hungary, Iceland, Norway,
Sweden)
Randomized controlled trial, double blind Industry
16 NCT00858780
(DOSERA) b
Europe (Denmark, Finland) Randomized controlled trial, double blind Industry
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population, exposure, follow-up and unbiased assess-
ment at the study end-point. In another recent system-
atic review and meta-analysis by Kuijper et al. the
estimated relapse rates were 0.26 (95% CI 0.17 to 0.39)
for high-quality studies and 0.49 (95% CI 0.27 to 0.73)
for moderate-quality studies. However, unlike our study,
focused on complete withdrawal of TNF-α inhibitors,
the meta-analysis by Kuijper et al. also included studies
reporting dose tapering [24].
A meta-analysis of six trials reported that TNF-α in-
hibitor treatment continuation, in RA patients in sus-
tained remission or low disease activity, increased the
probability of low disease activity (relative risk [RR] =
0.66, 95% CI 0.51–0.84) and remission (0.57, 95% CI
0.44–0.74), and reduced radiographic progression (RR =
0.91, 95% CI 0.85–0.98) [25]. Further, incidence of ser-
ious adverse events, serious infection, malignancy, and
scores of improvement of tender and swollen joints be-
tween these strategies were not significantly different.
About half of the patients withdrawing biologicals main-
tained low disease activity [25]. Similarly, an earlier
study in 91 RA patients receiving the TNF-α inhibitor
etanercept showed that a significantly higher number of
patients stayed in remission with continued therapy vs.
treatment withdrawal (52% vs. 13%; P = 0.007). The latter
group also had a very short time to failure (median of 6
weeks) as compared to those on full dose (48 weeks; P =
0.001). Patients on continued therapy were more effi-
cient in regaining remission after a flare-up [9].
The observed pooled relapse rate post-TNF-α inhibitor
withdrawal in our study provides important quantitative
data that complement existing information regarding re-
lapse rates after discontinuation of other DMARD ther-
apies in RA patients. The latter have been reported to be
40.0–78.9% with penicillamine [26, 27], 66.7% with aza-
thioprine [26, 28], 100% with methotrexate [26, 29],
33.3% with gold [26], and 47.1% with sulphasalazine
[26]. However, a direct comparison of relapse rates with
Table 3 Jadad score for the RCTs
Sl No. Study Name Question 1 Question 2 Question 3 Total Score
1 Quinn et al., 2005 1 1 1 3
2 Smolen et al., 2013 1 1 1 3
3 Moghadam et al., 2016 1 0 1 2
4 NCT00858780 (DOSERA) 1 1 1 3
5 NCT00858780 (DOSERA) b 1 1 1 3
Table 4 Methodological quality of the non-RCTs as per CASP checklist
Sl Study Name Clearly
focused
issue
Recruitment
acceptable
Exposure
measured
accurately
Outcome
measured
accurately
Identified all
confounders
Confounders
accounted for
Follow-up
complete
Follow up
long enough
1 Nawata et al.,
2008
Yes Yes Yes Yes Yes Yes Yes Yes
2 Brocq et al.,
2009
Yes Yes Yes Yes Yes Yes Yes Yes
3 Tanaka et al.,
2010
Yes Yes Yes Yes Yes Yes Yes Yes
4 van den Broek
et al., 2011
Yes Yes Yes Yes Yes Yes Cannot tell Yes
5 van den Massk
et al., 2012
Yes Yes Yes Yes Yes Yes Yes Yes
6 Harigai et al.,
2012
Yes Yes Yes Yes Yes Yes Yes Yes
7 Hirata et al.,
2013
Yes Yes Yes Yes Yes Yes Yes Yes
8 Iwamoto et al.,
2014
Yes Yes Yes Yes Yes Yes Yes Yes
9 Kádár et al.,
2014
Yes Yes Yes Yes Yes Yes Yes Yes
10 Tanaka et al.,
2015
Yes Yes Yes Yes Yes Yes Yes Yes
11 NCT00808509
(ADMIRE)
Yes Yes Yes Yes Yes Yes Yes Yes
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various DMARDs is rendered difficult because of the dif-
ferent baseline clinical characteristics, concomitant RA
treatment, methods to assess relapse, and follow-up in
individual studies. Furthermore, the RA treatment strat-
egies investigated in these relatively old studies are quite
different from those recommended by current profes-
sional guidelines.
All the studies included in this analysis, employing
rigid criteria for measuring disease activity and monitor-
ing remission, used improvement in DAS28 scoring sys-
tem. This is a widely used and recommended criterion
[30]. However, this in itself could be one of the key rea-
sons for higher relapse rates. A recent conference paper
showed that total dependence on DAS28 for monitoring
complete remission may not be a reliable method to en-
sure that patients remain in remission [31]. This study
used DAS28 to monitor disease activity and ACR/
EULAR 2010 criteria to measure response to therapy
coupled with MRI for dominant joint erosions. 73% of
the patients showing improvement in DAS28 score after
12 months also showed decrease in erosions, while 24%
had increased erosions. 41% patients who attained re-
mission as per EULAR score also had increased erosions.
40% of all the patients, despite showing improvements
in DAS28 score, continued to undergo progressive ero-
sive arthritis. It is highly likely that patients from the
Fig. 2 Pooled relapse rates in RA patients after elective withdrawal of anti-TNF therapies
Fig. 3 Sensitivity analysis revealing the influence of individual studies on the pooled relapse rates
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studies included in our analysis also had undergone con-
tinued erosions even after DAS28 improvements. As a
result, it is possible that the relapse rate in ‘real-life’ is
even higher than that (47%) reported in our
meta-analysis.
The results of our meta-analysis provide much
needed information regarding the magnitude of the
overall risk of relapse in RA patients receiving
TNF-α inhibitor therapy, where treatment withdrawal
is being considered by the patient and/or the treat-
ing physician. However, some caution is required
when translating these results into routine clinical
practice because of the differences between studies
in the treatment duration with TNF-α inhibitors at
baseline, the criteria used to define TNF-α inhibitor
withdrawal eligibility and relapse, the concomitant
treatment with other DMARDs, and the duration of
follow-up. Further limitations include the relatively
small sample size of the selected studies and the fact
that relapse rates, not their severity, were
investigated.
Conclusions
Our study shows that elective TNF-α inhibitor with-
drawal in RA patients is associated with a relatively high
relapse rate. This information should be taken into ac-
count when considering this management strategy. Fur-
ther studies are required to identify whether specific
patient characteristics, TNF-α inhibitors discontinued, or
concomitant DMARDs independently predict the risk of
relapse in this patient group.
Fig. 4 Cumulative meta-analysis of trials studying relapse rates after elective withdrawal of anti-TNF therapy in RA patients
Fig. 5 Funnel plot of standard error by log odds ratio
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